Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2017-10-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.7b01444PMID 28985084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proteomic Profiling

  2020cited by this paper
• Identification of novel TACE inhibitors compatible with topical application.

  2017cited by this paper
• Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.

  2017cited by this paper
• Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.

  2017cited by this paper
• Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies

  2016cited by this paper
• Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity.

  2016cited by this paper
• Structure Property Relationships of Carboxylic Acid Isosteres

  2016cited by this paper
• Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice

  2015cited by this paper
• Identification and activity of inhibitors of the essential nematode-specific metalloprotease DPY-31

  2015cited by this paper
• Hydroxamic acids block replication of hepatitis C virus.

  2015cited by this paper
• Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.

  2015cited by this paper
• Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors.

  2015cited by this paper
• Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

  2014cited by this paper
• Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors.

  2014cited by this paper
• Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.

  2014cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• Inhibition of aggrecanases as a therapeutic strategy in osteoarthritis.

  2014cited by this paper
• The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance?

  2013cited by this paper
• Species difference of esterase expression and hydrolase activity in plasma.

  2012cited by this paper
• Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.

  2012cited by this paper
• Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.

  2012cited by this paper
• Palladium-catalyzed double arylations of terminal olefins in acetic acid

  2012cited by this paper
• The emerging role of human esterases.

  2012cited by this paper
• The classification of esterases: an important gene family involved in insecticide resistance--a review.

  2012cited by this paper
• Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.

  2012cited by this paper
• Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.

  2012cited by this paper
• A facile synthesis of 1,5-disubstituted-2-aminoimidazoles: antibiotic activity of a first generation library.

  2011cited by this paper
• Comparative Analysis of Esterase Activities of Human, Mouse, and Rat Blood

  2011cited by this paper
• New Huprine Derivatives Functionalized at Position 9 as Highly Potent Acetylcholinesterase Inhibitors

  2011cited by this paper
• Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1

  2011cited by this paper
• Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.

  2011cited by this paper
• Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor

  2010cited by this paper
• Esterase activities in the blood, liver and intestine of several preclinical species and humans.

  2009cited by this paper
• Multi-catalysis cascade reactions based on the methoxycarbonylketene platform: diversity-oriented synthesis of functionalized non-symmetrical malonates for agrochemicals and pharmaceuticals.

  2009cited by this paper
• Hydroxamates: relationships between structure and plasma stability.

  2009cited by this paper
• Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.

  2009cited by this paper
• Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.

  2008cited by this paper
• β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents

  2008cited by this paper
• beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.

  2008cited by this paper
• Pseudo-esterase Activity of Human Albumin

  2008cited by this paper
• Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs

  2008cited by this paper
• Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).

  2008cited by this paper
• α,β-Cyclic-β-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-α converting enzyme (TACE)

  2008cited by this paper
• Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.

  2007cited by this paper
• Discovery and refinement of a new structural class of potent peptide deformylase inhibitors.

  2007cited by this paper
• Mild and efficient Lewis acid-promoted detritylation in the synthesis of N-hydroxy amides: a concise synthesis of (-)-Cobactin T.

  2007cited by this paper
• Virtues and woes of AChE alternative splicing in stress-related neuropathologies.

  2006cited by this paper
• Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

  2006cited by this paper
• Proteomic profiling of metalloprotease activities with cocktails of active-site probes

  2006cited by this paper
• Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.

  2006cited by this paper
• Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine

  2006cited by this paper
• Stability studies of vorinostat and its two metabolites in human plasma, serum and urine.

  2006cited by this paper
• Improved solution- and solid-phase preparation of hydroxamic acids from esters.

  2005cited by this paper
• Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.

  2005cited by this paper
• Novel sulfonamide derivatives as inhibitors of histone deacetylase

  2005cited by this paper
• Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.

  2005cited by this paper
• Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

  2004cited by this paper
• Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

  2004cited by this paper
• Corrigendum: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

  2004cited by this paper
• Hydroxamic Acids — An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands

  2004cited by this paper
• Hydroxamic Acids − An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands

  2004cited by this paper
• NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.

  2002cited by this paper
• Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase. Part 2: Solid-phase optimization of side chains.

  2002cited by this paper
• Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.

  2002cited by this paper
• A fluorescence-based homogeneous assay for measuring activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase.

  2001cited by this paper
• Soft drugs. 12. Design, synthesis, and evaluation of soft bufuralol analogues.

  2000cited by this paper
• Protease inhibitors

  2000cited by this paper
• The Tumor Necrosis Factor-α Converting Enzyme

  2000cited by this paper
• Protease inhibitors. Part 7. Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of L-valine hydroxamate.

  2000cited by this paper
• Matrix metalloproteinase inhibitors: a structure-activity study.

  1998cited by this paper
• Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.

  1998cited by this paper
• Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.

  1997cited by this paper
• Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases.

  1995cited by this paper
• Reductase activity of aldehyde oxidase toward the carcinogen N-hydroxy-2-acetylaminofluorene and the related hydroxamic acids.

  1994cited by this paper
• Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines.

  1983cited by this paper

• Photochemical Nickel‐Catalyzed Hydrocyanation of Unactivated Alkenes Using Isonitriles†

  2025cites this paper
• Mechanism of hydroxamic acid group metabolism to carboxylic acid: Oxidation versus hydrolysis.

  2025cites this paper
• Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors.

  2025cites this paper
• Ureases in nature: Multifaceted roles and implications for plant and human health - A review.

  2025cites this paper
• Probing into the plasma stability and microsomal stability of thiol-based prodrug derivatives: Using IYS-15, an HDAC inhibitor as the model thiol.

  2025cites this paper
• The regulatory mechanisms and treatment of HDAC6 in immune dysregulation diseases

  2025cites this paper
• Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?

  2024cites this paper
• Design and synthesis of non-hydroxamate lipophilic inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): in silico, in vitro and antibacterial studies

  2024cites this paper
• Drug Metabolism Mechanisms And Pharmacokinetics Strategies In Implications For Drug Design: A Comprehensive Review

  2024cites this paper
• Central Nervous System Distributional Kinetics of Selected Histone Deacetylase Inhibitors.

  2024cites this paper
• Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile

  2024cites this paper
• Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability

  2024cites this paper
• Investigations of Thiosemicarbazides as Botulinum Toxin Active-Site Inhibitors: Enzyme, Cellular, and Rodent Intoxication Studies.

  2024cites this paper
• PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor.

  2024cites this paper
• A Reaction of N-Substituted Succinimides with Hydroxylamine as a Novel Approach to the Synthesis of Hydroxamic Acids

  2023cites this paper
• Design, Synthesis and Bioactivity Evaluation of Heterocycle-Containing Mono- and Bisphosphonic Acid Compounds

  2023cites this paper
• Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.

  2023cites this paper
• Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.

  2023cites this paper
• Design, synthesis, and histone deacetylase inhibition study of novel 4‐(2‐aminoethyl) phenol derivatives

  2023cites this paper
• Quisinostat is a brain-penetrant radiosensitizer in glioblastoma

  2022cites this paper
• Enzymatic amide bond formation: synthesis of aminooxo-acids through a Mycobacterium smegmatis acyltransferase

  2022cites this paper
• Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

  2022cites this paper
• Silica Xerogel Doped with Iron(III) as Sensor Material for Salicylhydroxamic Acid Determination in Urine

  2021cites this paper
• Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain.

  2021cites this paper
• Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.

  2021cites this paper
• Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

  2021cites this paper
• Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity

  2021cites this paper
• Molecular Design in Practice: A Review of Selected Projects in a French Research Institute That Illustrates the Link between Chemical Biology and Medicinal Chemistry

  2021cites this paper
• Peptides Derived from Vascular Endothelial Growth Factor B Show Potent Binding to Neuropilin‐1

  2021cites this paper
• Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

  2020cites this paper
• Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective.

  2020cites this paper
• OleD Loki as a Catalyst for Hydroxamate Glycosylation

  2020cites this paper
• Environmentally benign decarboxylative N-, O-, and S-acetylations and acylations

  2020cites this paper
• Synthesis and Properties of N,N′-Disubstituted Ureas and Their Isosteric Analogs Containing Polycyclic Fragments: III. Synthesis and Properties ofN-[2-(Adamantan-1-yl)ethyl]-N′-R-ureas

  2020cites this paper
• Structure-based design of selective histone deacetylase 6 zinc binding groups

  2020cites this paper
• Synthesis and characterisation of Co(iii) complexes of N-formyl hydroxylamines and antibacterial activity of a Co(iii) peptide deformylase inhibitor complex.

  2020cites this paper
• Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.

  2020cites this paper
• Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation

  2020cites this paper
• Elucidating the binding propensity of naphthyl hydroxamic acid to human serum albumin (HSA): Multi-spectroscopic and molecular modeling approach

  2019cites this paper
• Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5'-Nucleotidase Inhibitors.

  2019cites this paper
• A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)

  2019cites this paper
• Kinetic Target-Guided Synthesis: reaching the age of maturity.

  2019cites this paper
• Assembly‐Induced Diverse Optical Property of 4‐Biphenylcarboxy‐Protected Serine and Tyrosine

  2019cites this paper
• The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma

  2019cites this paper
• Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

  2019cites this paper
• Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.

  2019cites this paper
• HDAC inhibitors: a 2013–2017 patent survey

  2018cites this paper
• Demonstration of the Anthelmintic Potency of Marimastat in the Heligmosomoides polygyrus Rodent Model

  2018cites this paper
• Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

  2018cites this paper
• Structure-Guided Design, Synthesis, and Characterization of Next-Generation Meprin β Inhibitors.

  2018cites this paper
• Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes.

  2018cites this paper